Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors - Institut Pierre Louis d'Epidémiologie et de Santé Publique Accéder directement au contenu
Article Dans Une Revue Infectious Diseases Now Année : 2021

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

Résumé

Background Tuberculosis is associated with a risk of immune reconstitution inflammatory syndrome (IRIS) after ART initiation. Methods Data from all patients with newly diagnosed tuberculosis disease and uncontrolled HIV infection from 1997 to 2017 in a French center were retrospectively collected. We evaluated the incidence of tuberculosis-IRIS in patients initiating ART with or without integrase inhibitors (INSTI) Results Fifty-five patients were included: 21 receiving an INSTI regimen and 34 a non-INSTI regimen. Except with regard to ART regimen, the two groups were comparable (median CD4 of 85/mm3). The overall percentage of IRIS was 34% (19/55), with 52% IRIS in INSTI regimen and 23% in non-INSTI regimen respectively (P = 0.04). In a multivariate logistic model, we observed an increased risk of IRIS in the INSTI regimen compared to the non-INSTI, with an OR at 3.33 [95% CI, 1.01–11.1] (P = 0.05) Conclusions ART containing integrase inhibitors could be associated with increased incidence of TB-associated IRIS.
Fichier principal
Vignette du fichier
Gaillet et al. - 2021 - Increased risk of IRIS-associated tuberculosis in .pdf (1.23 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03280354 , version 1 (07-07-2021)

Identifiants

Citer

A. Gaillet, R. Calin, P. Flandre, R. Tubiana, M.-A. Valantin, et al.. Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors. Infectious Diseases Now, 2021, 51 (1), pp.90-93. ⟨10.1016/j.medmal.2020.09.005⟩. ⟨hal-03280354⟩
9 Consultations
63 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More